We are live on
!
Find out more
GC
Grace Capital Portfolio holdings
AUM
$168M
1-Year Est. Return
21.6%
This Fund
S&P 500
This Quarter
Est. Return
+18.02%
1 Year Est. Return
+21.6%
3 Year Est. Return
+126.68%
5 Year Est. Return
+161.89%
10 Year Est. Return
–
AUM
$256M
AUM Growth
+$40.8M
(+19%)
Cap. Flow
+$11.8M
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
25.74%
Holding
236
New
24
Increased
57
Reduced
82
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$8.05M |
| 2 |
IBM
IBM
|
+$3.95M |
| 3 |
Vanguard Health Care ETF
VHT
|
+$3.42M |
| 4 |
Vanguard Consumer Discretionary ETF
VCR
|
+$3.18M |
| 5 |
Vanguard Communication Services ETF
VOX
|
+$3.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$4.09M |
| 2 |
Gentex
GNTX
|
+$1.95M |
| 3 |
SiriusXM
SIRI
|
+$1.89M |
| 4 |
VeriSign
VRSN
|
+$1.63M |
| 5 |
Novartis
NVS
|
+$1.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.16% |
| 2 | Healthcare | 16.63% |
| 3 | Financials | 9.69% |
| 4 | Consumer Discretionary | 8.9% |
| 5 | Communication Services | 6.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $14M | 5.45% |
264,014
+163,885
| +164% | +$8.05M |
|
|
PTLA
2
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $11.2M | 4.36% |
322,132
+42,923
| +15% | +$1.24M |
|
3
Apple
AAPL
$4.9T
| $6.77M | 2.64% |
142,560
+6,208
| +5% | +$263K |
|
4
Microsoft
MSFT
$2.93T
| $5.86M | 2.29% |
49,683
-12,330
| -20% | -$1.35M |
|
5
JPMorgan Chase
JPM
$907B
| $4.92M | 1.92% |
48,560
-1,058
| -2% | -$109K |
|
6
Amazon
AMZN
$2.66T
| $4.85M | 1.89% |
56,400
+6,180
| +12% | +$514K |
|
7
Cisco
CSCO
$441B
| $4.74M | 1.85% |
87,727
-1,160
| -1% | -$56.4K |
|
8
Visa
V
$682B
| $4.65M | 1.82% |
29,798
+990
| +3% | +$143K |
|
9
Alphabet (Google) Class C
GOOG
$4.22T
| $4.54M | 1.77% |
77,380
+9,460
| +14% | +$531K |
|
10
Pfizer
PFE
$143B
| $4.49M | 1.75% |
111,313
-25,411
| -19% | -$1.02M |
|
11
Cheniere Energy
CQP
$30.2B
| $4.31M | 1.68% |
102,755
+73,105
| +247% | +$3.01M |
|
|
12
IBM
IBM
$200B
| $4.18M | 1.63% |
+30,988
| New | +$3.95M |
|
13
Walmart Inc
WMT
$909B
| $4.14M | 1.62% |
127,509
+591
| +0.5% | +$19.2K |
|
|
14
Vanguard Consumer Discretionary ETF
VCR
$6.15B
| $3.79M | 1.48% |
21,969
+19,265
| +712% | +$3.18M |
|
15
Johnson & Johnson
JNJ
$609B
| $3.76M | 1.47% |
26,893
-5,924
| -18% | -$794K |
|
16
Crown Castle
CCI
$34.6B
| $3.65M | 1.42% |
28,475
+16,394
| +136% | +$1.92M |
|
17
Boeing
BA
$169B
| $3.59M | 1.4% |
9,489
+1,308
| +16% | +$504K |
|
|
18
Vanguard Health Care ETF
VHT
$18B
| $3.48M | 1.36% |
+20,188
| New | +$3.42M |
|
|
FISV
19
Fiserv Inc
FISV
$27B
| $3.48M | 1.36% |
39,358
-4,146
| -10% | -$342K |
|
20
Bank of America
BAC
$430B
| $3.3M | 1.29% |
119,733
+2,490
| +2% | +$70.4K |
|
|
21
Vanguard Communication Services ETF
VOX
$5.78B
| $3.23M | 1.26% |
+38,704
| New | +$3.16M |
|
22
Adobe
ADBE
$94.3B
| $2.97M | 1.16% |
11,153
-44
| -0.4% | -$11.1K |
|
23
UnitedHealth
UNH
$387B
| $2.68M | 1.04% |
10,825
-2,885
| -21% | -$736K |
|
|
OPLN
24
Openlane
OPLN
$4.18B
| $2.56M | 1% |
131,548
-15,292
| -10% | -$288K |
|
25
Comcast
CMCSA
$85B
| $2.53M | 0.99% |
63,195
+2,603
| +4% | +$97.9K |
|
Similar funds
REMS
TI
NM
KM
MC
FAC
MSO
ACM
Grace Capital's Q1 2019 Portfolio in Review
As of Q1 2019, Grace Capital held 236 positions worth $256M, up 19% from $215M the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Grace Capital deployed $11.8M of net new capital in Q1 2019, opening 24 new positions and adding to 57 existing holdings. Its largest new stake was IBM: 30,988 shares worth $4.18M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was MyoKardia, Inc. Common Stock, an estimated $4.09M trimmed.
- Grace Capital's largest Q1 2019 buy was IBM: 30,988 shares worth $4.18M.
- Grace Capital added most to Global Blood Therapeutics, Inc. in Q1 2019, an estimated $8.05M increase.
- Grace Capital's biggest Q1 2019 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $4.09M.
- Grace Capital fully exited Gentex in Q1 2019, selling an estimated $1.95M.
- Grace Capital's ten largest holdings make up 26% of its $256M portfolio in Q1 2019.
- Grace Capital opened 24 new positions and closed 36 in Q1 2019.
- Grace Capital's portfolio value rose 19% quarter-over-quarter to $256M.
Based on Grace Capital's 13F filing for Q1 2019, filed 15 May 2019.